Literature DB >> 20807186

Conformational diseases: structural studies of aggregation of polyglutamine proteins.

Elena Papaleo1, Gaetano Invernizzi.   

Abstract

Protein misfolding and aggregation into insoluble amyloid deposits are often associated with neurodegenerative disorders. In particular, the polyglutamine (polyQ) diseases are inherited disorders triggered by the expansion of the polyQ tract over its physiological length in the involved protein. The molecular mechanism of aggregation from the native protein into amyloids involves several steps including protein misfolding, aggregation into oligomers, which seems to be the most toxic species, and, finally rearrangements into mature fibrils. In the present contribution, we review studies, integrating computational and experimental approaches, of polyQ proteins, as well as of the details of the complicate aggregation mechanisms in which aberrant form of polyQ proteins are involved. These aspects are of crucial relevance for a complete understanding of the onset of polyQ conformational diseases and can also shed light on putative therapeutic targets and future development of aggregation inhibitors.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 20807186     DOI: 10.2174/157340911793743574

Source DB:  PubMed          Journal:  Curr Comput Aided Drug Des        ISSN: 1573-4099            Impact factor:   1.606


  4 in total

1.  DNAJB6 is a peptide-binding chaperone which can suppress amyloid fibrillation of polyglutamine peptides at substoichiometric molar ratios.

Authors:  Cecilia Månsson; Vaishali Kakkar; Elodie Monsellier; Yannick Sourigues; Johan Härmark; Harm H Kampinga; Ronald Melki; Cecilia Emanuelsson
Journal:  Cell Stress Chaperones       Date:  2013-08-01       Impact factor: 3.667

2.  The Protein Structure Context of PolyQ Regions.

Authors:  Franziska Totzeck; Miguel A Andrade-Navarro; Pablo Mier
Journal:  PLoS One       Date:  2017-01-26       Impact factor: 3.240

3.  Conformational studies of pathogenic expanded polyglutamine protein deposits from Huntington's disease.

Authors:  Irina Matlahov; Patrick Ca van der Wel
Journal:  Exp Biol Med (Maywood)       Date:  2019-06-15

4.  ATXN1 N-terminal region explains the binding differences of wild-type and expanded forms.

Authors:  Sara Rocha; Jorge Vieira; Noé Vázquez; Hugo López-Fernández; Florentino Fdez-Riverola; Miguel Reboiro-Jato; André D Sousa; Cristina P Vieira
Journal:  BMC Med Genomics       Date:  2019-10-26       Impact factor: 3.063

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.